Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ceragenix Pharmaceuticals has entered into an exclusive distribution and supply agreement with Dr Reddy's Laboratories, Inc, a subsidiary of Dr Reddy's Laboratories Limited, to commercialize EpiCeram, a prescription topical cream for treating atopic dermatitis and other dry skin conditions, in the US.
Subscribe to our email newsletter
The agreement grants Dr Reddy’s exclusivity in the US for the distribution and marketing of EpiCeram while Ceragenix will be responsible for the manufacturing and supply of the product. Under the agreement, Ceragenix will receive certain milestone payments over the agreement period. Upon commercialization of the product, Ceragenix will receive royalty payments based on net sales. Dr Reddy’s expects to launch EpiCeram within a year through a new salesforce targeting dermatologists.
Steven Porter, chairman and CEO of Ceragenix, said: “We are very pleased to be partnering with Dr Reddy’s to commercialize EpiCeram. We are very impressed with the team assembled by Dr Reddy’s and we look to forward bringing this product into the market together. As we’ve stated in the past, we believe that patients and physicians alike will find EpiCeram’s combination of efficacy and safety profile to be a welcome alternative in the treatment of atopic dermatitis.”
http://biz.yahoo.com/bw/071119/20071119005423.html?.v=1